Appl. No. 10/538,904

Amdt. Dated April 22, 2008

Reply to Office action of Jan. 24, 2008

## Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

## Listing of Claims:

 (Currently Amended) A process for the production of an <sup>18</sup>F-labelled tracer which comprises treatment of a solid support-bound precursor of formula (I):

Y-

wherein the TRACER is of formula (A):

$$\stackrel{\mathsf{H}}{\underset{\mathsf{R}^1-\mathsf{N}}{\longleftarrow}}$$
 $\circ$  (A)

or an amine protected derivative thereof, wherein  $Y^-$  is an anion, preferably trifluoromethylsulphonate (triflate) anion; and

 $R^1$  is either (i) a group CH-NP<sup>1A</sup>P<sup>2A</sup> in which  $P^{1A}$  and  $P^{2A}$  are each independently hydrogen or a protecting group, or (ii) a carbonyl group;

with 18F to produce the labelled tracer of formula (II)

$$^{18}F \longrightarrow \stackrel{\stackrel{\stackrel{}}{\stackrel{}}}{\stackrel{\stackrel{}}{\stackrel{}}{\stackrel{}}} = 0$$
 (II)

or an amine protected derivative thereof, wherein R<sup>1</sup> is as defined for the compound of formula (I);

optionally followed by:

(i) removal of excess  $^{18}\mbox{F}^{\mbox{-}}$  , for example by ion-exchange chromatography; and/or

Reply to Office action of Jan. 24, 2008

- (ii) removal of any protecting groups; and/or
- (iii) removal of organic solvent; and/or
- (iv) formulation of the resultant compound of formula (II) as an aqueous solution.
- (Currently Amended) A process according to claim 1 for the production of 5[18F]fluorouracil which comprises treatment of a solid support-bound precursor of formula (Ia):

or an amine protected derivative thereof, wherein Y is an anion, preferably trifluoromethylsulphonate (triflate) anion;

with 18F to produce the labelled tracer of formula (IIa)

or an amine protected derivative thereof, optionally followed by:

- (i) removal of excess <sup>18</sup>F<sup>-</sup>, for example by ion-exchange chromatography; and/or
- (ii) removal of organic solvent; and/or
- (iii) removal of any protecting groups; and/or
- (iv) formulation of the resultant compound of formula (IIa) as an aqueous solution.
- 3. (Withdrawn) A process according to claim 1 for the production of  $5[^{18}F]$ fluorocytosine which comprises treatment of a solid support-bound precursor of formula (Ib):

Appl. No. 10/538,904 Amdt. Dated April 22, 2008 Reply to Office action of Jan. 24, 2008

SOLID SUPPORT-LINKER-I\* 
$$\stackrel{Y^{\cdot}}{\underset{P^{2A}P^{1A}N}{\longleftarrow}} \stackrel{H}{\underset{HC}{\longleftarrow}} O$$
 (Ib)

or an amine protected derivative thereof, wherein Y is an anion, preferably trifluoromethylsulphonate (triflate) anion,  $P^{1A}$  and  $P^{2A}$  are independently hydrogen or a protecting group;

with 18F to produce the labelled tracer of formula (IIb)

or an amine protected derivative thereof, wherein  $P^{1A}$  and  $P^{2A}$  are as defined for the compound of formula (1b), optionally followed by:

- (i) removal of excess <sup>18</sup>F-, for example by ion-exchange chromatography; and/or
- (ii) removal of organic solvent; and/or
- (iii) removal of any protecting groups; and/or
- (iv) formulation of the resultant compound of formula (IIb) as an aqueous solution.
- 4. (Withdrawn) A process for the production of an <sup>18</sup>F-labelled tracer which comprises treatment of a compound of formula (III), (IIIa), or (IIIb):

$$\begin{array}{c|c}
B & \downarrow & \downarrow & \downarrow \\
Y & R^{1} - N & \downarrow & \downarrow \\
Y & R^{1} - N & \downarrow & \downarrow \\
\end{array}$$
(III)

Reply to Office action of Jan. 24, 2008

or an amine protected derivative thereof, wherein  $R^1$ ,  $P^{2A}$ ,  $P^{1A}$ , and Y are as defined in claim 1, and phenyl ring B is optionally substituted with one to five substituents independently selected from halo,  $C_{1-6}$  alkyl,  $C_{1-6}$  haloalkyl, hydroxy,  $C_{1-6}$  alkoxy, amino,  $C_{1-6}$  hydroxyalkyl, and nitro:


with <sup>18</sup>F to produce the labelled tracer of formula (II), (IIa), or (IIb) respectively as defined in claims 1 to 3 or an amine protected derivative thereof, optionally followed by:

- (i) removal of excess <sup>18</sup>F , for example by ion-exchange chromatography; and/or
- (ii) removal of any protecting groups; and/or
- (iii) removal of organic solvent; and/or
- (iv) formulation of the resultant compound of formula (II), (IIa), or (IIb) as an aqueous solution.
- (Currently Amended) A process for the production of a <sup>18</sup>F-labelled tracer of formula (II), according to claim 1, for use in PET which comprises treatment of a solid support-bound precursor of formula (I):

Y

wherein the TRACER is of formula (A):

Reply to Office action of Jan. 24, 2008



wherein  $Y^-$  is an anion, preferably trifluoromethylsulphonate (triflate) anion; and  $R^{\perp}$  is either (i) a group CH-NP $^{1\Delta}$ P $^{2\Delta}$  in which  $P^{1\Delta}$  and  $P^{2\Delta}$  are each independently hydrogen or a protecting group, or (ii) a carbonyl group;

wherein R<sup>1</sup> is as defined for the compound of formula (I);

optionally followed by:

- (i) removal of excess 18 F-, for example by ion-exchange chromatography; and/or
- (ii) removal of any protecting groups; and/or
- (iii) removal of organic solvent; and/or
- (iv) formulation of the resultant compound of formula (II) as an aqueous solution.
- 6. (Currently Amended) A compound of formula (I):

SOLID SUPPORT-LINKER-
$$I^+$$
-TRACER (I)  
 $Y^-$ 

wherein the TRACER is of formula (A):

$$- \bigvee_{R^1 - N}^{H} = 0 \qquad (A)$$

or an amine protected derivative thereof, wherein  $Y^-$  is an anion, preferably trifluoromethylsulphonate (triflate) anion; and

 $R^{1}$  is either (i) a group CH-NP<sup>1A</sup>p<sup>2A</sup> in which  $P^{1A}$  and  $P^{2A}$  are each independently hydrogen or a protecting group, or (ii) a carbonyl group.

Reply to Office action of Jan. 24, 2008

7. (Currently Amended) A compound of formula (Ia):

SOLID SUPPORT-LINKER-I\* 
$$V$$
  $C$   $H$   $O$   $(Ia)$ 

or an amine protected derivative thereof, wherein  $Y^-$  is an anion, preferably trifluoromethylsulphonate (triflate) anion.

8. (Withdrawn) A compound of formula (Ib):

SOLID SUPPORT-LINKER-I\*
$$\begin{array}{c} Y \\ \\ HC - N \\ P^{2A}P^{1A}N \end{array}$$
(Ib)


or an amine protected derivative thereof, wherein  $Y^-$  is an anion, preferably trifluoromethylsulphonate (triflate) anion,  $P^{1A}$  and  $P^{2A}$  are independently hydrogen or a protecting group.

 (Currently Amended) A radiopharmaceutical kit for the preparation of an <sup>18</sup>F-labelled tracer for use in PET, which comprises treatment of a solid support-bound precursor of formula (I):

Y

wherein the TRACER is of formula (A):

Reply to Office action of Jan. 24, 2008




wherein  $Y^-$  is an anion, preferably trifluoromethylsulphonate (triflate) anion; and  $R^{\perp}$  is either (i) a group CH-NP $^{1\Delta}$ P $^{2\Delta}$  in which  $P^{1\Delta}$  and  $P^{2\Delta}$  are each independently hydrogen or a protecting group, or (ii) a carbonyl group;

wherein R1 is as defined for the compound of formula (I):

which comprises:

- (i) a vessel containing a compound of formula (I), as defined in claim 1, or an amine protected derivative thereof; and
- (ii) means for eluting the vessel with a source of 18F;
- (iii) an ion-exchange cartridge for removal of excess 18F; and optionally
- (iv) a cartridge for solid-phase deprotection of the resultant product of formula (II), claim 1.
- 10. (Currently Amended) A cartridge for a radiopharmaceutical kit for the preparation of an <sup>18</sup>F-labelled tracer for use in PET which comprises <u>treatment of a solid support-bound</u> precursor of formula (I):

wherein the TRACER is of formula (A):



wherein  $Y^-$  is an anion, preferably trifluoromethylsulphonate (triflate) anion; and  $R^1$  is either (i) a group CH-NP<sup>IA</sup> $P^{2\Delta}$  in which  $P^{1\Delta}$  and  $P^{2\Delta}$  are each independently hydrogen or a protecting group, or (ii) a carbonyl group;

Appl. No. 10/538,904

Amdt. Dated April 22, 2008

Reply to Office action of Jan. 24, 2008

## wherein R<sup>1</sup> is as defined for the compound of formula (I); further wherein

- (i) a vessel containing a compound of formula (I), as defined in claim 1, or an amine protected derivative thereof: and
- (ii) means for eluting the vessel with a source of <sup>18</sup>F-.
- 11. (Withdrawn) A method for obtaining a diagnostic PET image which comprises the step of using a radionharmaceutical kit according to claim 9.
- 12. (Previously presented) A method for obtaining a diagnostic PET image which comprises the step of using a cartridge for a radiopharmaceutical kit according to claim 10.